SEC Company Response from Cardiff Oncology, Inc. (CRDF) (CIK 0001213037) (CRDF) — Dec 13, 2017
Cardiff Oncology, Inc. (CRDF) (CIK 0001213037)
Date: Dec. 13, 2017 · CIK: 0001213037 · Accession: 0001193125-17-368405
AI Filing Summary & Sentiment
File numbers found in text: 333-221115
Letter
Trovagene, Inc.
11055 Flintkote Avenue
San Diego, CA 92921
December 13, 2017
VIA EDGAR
United States Securities
and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Christine Westbrook
Re: Trovagene Inc.
Registration Statement on Form S-1, as amended
File No. 333-221115
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:15 p.m., Eastern Standard Time, on Thursday, December 14, 2017, or as soon thereafter as possible. In connection with this request, the Company hereby acknowledges that:
•
Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
The Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Thank you,
TROVAGENE, INC.
By:
/s/ William Welch
Name:
William Welch
Title:
Chief Executive Officer
Show Raw Text
CORRESP 1 filename1.htm CORRESP Trovagene, Inc. 11055 Flintkote Avenue San Diego, CA 92921 December 13, 2017 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Westbrook Re: Trovagene Inc. Registration Statement on Form S-1, as amended File No. 333-221115 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Trovagene, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 5:15 p.m., Eastern Standard Time, on Thursday, December 14, 2017, or as soon thereafter as possible. In connection with this request, the Company hereby acknowledges that: • Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; • The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and • The Company may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Thank you, TROVAGENE, INC. By: /s/ William Welch Name: William Welch Title: Chief Executive Officer